1. Home
  2. HCAI vs GRDX Comparison

HCAI vs GRDX Comparison

Compare HCAI & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HCAI

Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

HOLD

Current Price

$0.15

Market Cap

6.3M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.16

Market Cap

7.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HCAI
GRDX
Founded
2004
N/A
Country
China
United Kingdom
Employees
N/A
2
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
7.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HCAI
GRDX
Price
$0.15
$2.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
816.6K
77.1K
Earning Date
05-23-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$63.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$1.87
52 Week High
$10.60
$5.30

Technical Indicators

Market Signals
Indicator
HCAI
GRDX
Relative Strength Index (RSI) 37.31 46.37
Support Level $0.13 $1.99
Resistance Level $0.20 $2.56
Average True Range (ATR) 0.02 0.22
MACD 0.00 0.05
Stochastic Oscillator 28.29 39.47

Price Performance

Historical Comparison
HCAI
GRDX

About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: